The Lundbeck Foundation delivers record-breaking result

The Lundbeck Foundation, which is the majority stakeholder in pharmaceutical firm Lundbeck, has had its best year to date, ending 2021 with a profit of DKK 6.9bn (USD 1bn).

Photo: Gregers Tycho/ERH

The very affluent majority owner of pharmaceutical firm Lundbeck, the Lundbeck Foundation, has just announced a historically good year, according to the foundation’s annual report for 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs